{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+to+Skin&page=21",
    "query": {
      "condition": "Skin to Skin",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 6435,
    "total_pages": 644,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+to+Skin&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+to+Skin&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T16:16:47.243Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03036488",
      "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Epirubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1174,
      "start_date": "2017-03-07",
      "completion_date": "2025-10-14",
      "has_results": true,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-24T16:16:47.243Z",
      "location_count": 47,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03036488"
    },
    {
      "nct_id": "NCT06727773",
      "title": "Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Locally Advanced Breast Cancer",
        "Cognitive Impairment",
        "Cognitive Decline",
        "Cognitive Change",
        "Breast Cancer Stage I",
        "Breast Cancer Stage II",
        "Breast Cancer Stage III"
      ],
      "interventions": [
        {
          "name": "Memantine",
          "type": "DRUG"
        },
        {
          "name": "Placebo medication",
          "type": "DRUG"
        },
        {
          "name": "Exercise Intervention",
          "type": "OTHER"
        },
        {
          "name": "Exercise Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 90,
      "start_date": "2025-08-19",
      "completion_date": "2029-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-24T16:16:47.243Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06727773"
    },
    {
      "nct_id": "NCT04214483",
      "title": "A Pilot Study to Explore the Role of Gut Flora in Acne",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acne",
        "Acne Vulgaris",
        "Acne Keloidalis",
        "Acne Keloid",
        "Acne Conglobata",
        "Acne Rosacea",
        "Acne Inversa",
        "Acne Cystic",
        "Acne Pomade",
        "Acne Indurata",
        "Acne Papular",
        "Acne Tropica",
        "Acne Urticata",
        "Acne Fulminans",
        "Acne Follicular",
        "Acne Tropicalis",
        "Acne Detergicans",
        "Acne Iodide",
        "Acne Varioliformis"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "ProgenaBiome",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2020-03-02",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-10-24T16:16:47.243Z",
      "location_count": 1,
      "location_summary": "Ventura, California",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04214483"
    },
    {
      "nct_id": "NCT05814627",
      "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 487,
      "start_date": "2023-06-15",
      "completion_date": "2026-07-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-24T16:16:47.243Z",
      "location_count": 85,
      "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more",
      "locations": [
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05814627"
    },
    {
      "nct_id": "NCT00162045",
      "title": "A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kawasaki Disease"
      ],
      "interventions": [
        {
          "name": "Technetium Tc99m Sestamibi",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lantheus Medical Imaging",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "4 Years to 16 Years"
      },
      "enrollment_count": 79,
      "start_date": "2005-01",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2011-06-02",
      "last_synced_at": "2026-10-24T16:16:47.243Z",
      "location_count": 7,
      "location_summary": "Miami, Florida • Honolulu, Hawaii • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00162045"
    },
    {
      "nct_id": "NCT00679770",
      "title": "Study of Different Doses of a Novel Treatment for Onychomycosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Distal, Subungual Onychomycosis"
      ],
      "interventions": [
        {
          "name": "AN2690, 2.5%",
          "type": "DRUG"
        },
        {
          "name": "AN2690, 5%",
          "type": "DRUG"
        },
        {
          "name": "AN2690, 7.5%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 28,
      "start_date": "2006-06-30",
      "completion_date": "2007-08-31",
      "has_results": false,
      "last_update_posted_date": "2018-02-20",
      "last_synced_at": "2026-10-24T16:16:47.243Z",
      "location_count": 4,
      "location_summary": "Albuquerque, New Mexico • Austin, Texas • Bryan, Texas + 1 more",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Bryan",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00679770"
    },
    {
      "nct_id": "NCT06423573",
      "title": "A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epidermolysis Bullosa, Dystrophic",
        "Epidermolysis Bullosa, Junctional"
      ],
      "interventions": [
        {
          "name": "Filsuvez",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 170,
      "start_date": "2024-12-18",
      "completion_date": "2032-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-24T16:16:47.243Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 3 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06423573"
    },
    {
      "nct_id": "NCT06210945",
      "title": "Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "10 mg/kg CM-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ChemomAb Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 45,
      "start_date": "2026-09",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-10-24T16:16:47.243Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06210945"
    },
    {
      "nct_id": "NCT05162846",
      "title": "Michigan Genetic Hereditary Testing (MiGHT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Pancreatic Cancer",
        "Endometrial Cancer",
        "History of Cancer"
      ],
      "interventions": [
        {
          "name": "Publicly available genetic testing resources",
          "type": "OTHER"
        },
        {
          "name": "Virtual genetics navigator",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Motivational interviewing (MI)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 793,
      "start_date": "2022-04-21",
      "completion_date": "2025-11-21",
      "has_results": true,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-24T16:16:47.243Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05162846"
    },
    {
      "nct_id": "NCT04553770",
      "title": "Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Early-stage Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma",
        "Invasive Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIB Breast Cancer",
        "Stage III Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2020-10-09",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-24T16:16:47.243Z",
      "location_count": 9,
      "location_summary": "Fullerton, California • Los Alamitos, California • Los Angeles, California + 6 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04553770"
    }
  ]
}